Across TCGA pan-cancer cohorts, GOLGA6B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GOLGA6B data layer compared with 19 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher GOLGA6B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GOLGA6B expression acts as an unfavorable survival marker.

LUSC and CHOL are the cancer types where GOLGA6B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.002	0.776	<.001	24	view →
CHOL	DFS	Median	All	0.045	0.486	.009	15	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: GOLGA6B tumor-vs-normal RNA expression · all GOLGA6B data types